Filing Details

Accession Number:
0001415889-24-021305
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-14 16:57:27
Reporting Period:
2024-08-12
Accepted Time:
2024-08-14 16:57:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1159036 Halozyme Therapeutics Inc. HALO Biological Products, (No Disgnostic Substances) (2836) 880488686
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1543792 L. Matthew Posard C/O Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego CA 92130
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-08-12 10,000 $55.72 89,755 No 4 S Direct
Common Stock Disposition 2024-08-13 10,000 $56.19 79,755 No 4 S Direct
Common Stock Disposition 2024-08-14 9,881 $57.70 69,874 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.70 to $55.825. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  2. Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director.
  3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.058 to $56.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.